| abstract |
Inhibitors of HCV proliferation of formula (I) and N-oxides, salts and stereoisomers, where each dotted line represents an optional double bond; X is N, CH and where X has a double bond, C is; R1 is -OR7 -, -NH-SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3- 7 is cycloalkyl; R 4 is aryl or Het; n is 3, 4, 5, or 6; R 5 is halo, C 1-6 alkyl, hydroxy, C 1-6 alkoxy, phenyl, or Het; R 6 is C 1-6 alkoxy, or dimethylamino · R7 is hydrogen · aryl · Het · C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl or C1-6alkyl; C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroat nitrogen, oxygen and sulfur, and are substituted e.g. solvents with one, two or three substituents; pharmaceutical compositions containing the compounds (I) and processes for the preparation of the compounds (I). Bioavailable combinations of HCV inhibitors of formula (I) with ritonavir are also provided. |